SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors are keenly focused on recent technical breakouts and the potential for S&P 500 inclusion, with many anticipating a pre-earnings rally. The community is actively debating the impact of recent capital raises and the upcoming stablecoin launch, alongside performance targets for the CEO. Bullish sentiment is countered by concerns over past share dilution and price volatility, though the broader fintech sector's momentum adds to the conversation.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending due to overwhelming short squeeze speculation, fueled by exorbitant borrow fees, limited share availability, and its inclusion on the Reg SHO list. The community is actively celebrating the stock sustaining above the critical $5 mark, which is seen as a gateway for institutional investment, and expressing high conviction in the groundbreaking potential of its GPS immunotherapy for AML. This confluence of factors, including promising clinical trial progress suggesting significantly extended patient survival, is driving intense discussion around a potential multi-billion dollar buyout and a significant re-rating of the company's value.

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Alumis Inc.

Alumis Inc. is trending following highly positive topline Phase 3 results for its oral TYK2 inhibitor, envudeucitinib, in moderate-to-severe plaque psoriasis, which demonstrated strong efficacy and met all primary and secondary endpoints. The biopharmaceutical company's robust data is fueling community excitement over its potential as a best-in-class oral therapy for immune-mediated diseases, with discussions also weighing its competitive landscape and future valuation.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending due to its strategic collaboration with OpenAI, enhancing its Athena AI marketing platform with advanced conversational intelligence, an announcement made at CES 2026. This news has ignited strong community discussion, with many anticipating a significant short squeeze given the stock's high short interest and perceived undervaluation. Investors are actively highlighting Zeta's position as a burgeoning leader in the AI-driven MarTech sector and its strengthening fundamentals.

Aeva Technologies, Inc. develops sensing paradigm for autonomous vehicles and robotics. The firm offers drones, robotics, vehicle technology, and virtual and augmented reality products. The company was founded by Soroush Salehian Dardashti and Mina Rezk in 2017 and is headquartered in Mountain View, CA.

Aeva Technologies Inc

Aeva Technologies is generating significant buzz after announcing its 4D LiDAR technology will be integrated into the NVIDIA DRIVE Hyperion platform, aiming for Level 4 self-driving capabilities. This major validation from an industry leader has ignited widespread community discussion about AEVA's strong potential in the autonomous vehicle sector, with many anticipating a significant impact due to its low float and the strategic partnership.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently experiencing a significant surge in trading volume, driving strong bullish sentiment and community discussions predicting a notable price ascent. The conversation highlights its foundational technology in IoT and decentralized data, bolstered by Japanese regulatory compliance and anticipated 2026 ecosystem developments, with many viewing it as a long-term investment in a real technology project.

Momentus, Inc. engages in the provision of in-space infrastructure services. It offers space transportation and in-orbit servicing. The company was founded by Mikhail Kokorich in 2017 and is headquartered in Santa Jose, CA.

Momentus Inc - Ordinary Shares - Class A

Momentus is trending due to the announcement of a 3D-printed fuel tank for its Vigoride-7 orbital vehicle, sparking excitement around the company's innovation in the space sector. This enthusiasm, however, is heavily contested by community members after a recent private placement was announced, fueling intense debate over potential dilution and the company's financial stability, despite its position in the trending space sector.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is experiencing a powerful bullish surge, fueled by substantial positive ETF inflows and impressive trading volumes that indicate strong institutional interest. The community is buzzing with optimism, anticipating a breakout to new levels and discussing XRP's potential to establish itself as a leader in the evolving crypto landscape, possibly decoupling from broader market trends.

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in Chicago, IL.

Bright Minds Biosciences Inc

Bright Minds Biosciences is currently trending following positive Phase 2 clinical data for BMB-101, showing strong efficacy and a clean safety profile in treating drug-resistant epilepsy. This promising update has ignited intense community discussion, with many drawing parallels to prior explosive biotech surges and debating the potential for a significant short squeeze, while others express surprise at the market's reaction despite the scientific advancements.

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Crypto is trending as its "Wolfpack" community rallies around the recently launched WolfSWAP, a cross-chain swap aggregator. Enthusiasts are actively touting its utility and commitment to decentralization, frequently drawing comparisons to early memecoin successes and urging others not to overlook the project. The strong bullish sentiment is further fueled by anticipation for an innovative flagship product expected to launch in early 2026.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

New Strong Buy Stocks for January 6th

ILPT, NMTC, RIGL, RIO and BHP have been added to the Zacks Rank #1 (Strong Buy) List on January 6th, 2026.

Rigel Pharmaceuticals, Inc. $RIGL Shares Sold by Voya Investment Management LLC

Voya Investment Management LLC lowered its stake in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 53.2% during the third quarter, according to the company in its most recent...

Pacer Advisors Inc. Buys New Position in Rigel Pharmaceuticals, Inc. $RIGL

Pacer Advisors Inc. bought a new position in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) during the third quarter, according to its most recent Form 13F filing with the...

Range Financial Group LLC Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGL

Range Financial Group LLC purchased a new position in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) in the third quarter, according to its most recent disclosure with the SEC. The...

Inspire Investing LLC Makes New $859,000 Investment in Rigel Pharmaceuticals, Inc. $RIGL

Inspire Investing LLC purchased a new stake in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with...

Assenagon Asset Management S.A. Decreases Holdings in Rigel Pharmaceuticals, Inc. $RIGL

Assenagon Asset Management S.A. reduced its stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 91.9% during the third quarter, according to its most recent filing with the SEC. The...

Rigel Pharmaceuticals (NASDAQ:RIGL) Upgraded to Buy at Wall Street Zen

Wall Street Zen raised Rigel Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Sunday...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Recommendation of "Hold" from Analysts

Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) have received an average rating of "Hold" from the seven research firms that are covering the stock, Marketbeat reports. Four...

Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded to "Hold" Rating by Wall Street Zen

Wall Street Zen lowered shares of Rigel Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday...

Armistice Capital LLC Acquires 84,000 Shares of Rigel Pharmaceuticals, Inc. $RIGL

Armistice Capital LLC increased its holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 5.5% in the 2nd quarter, according to its most recent disclosure with the Securities...

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

Current Price	$41.19
Prev Close	$41.83
Open	$41.70
Dividend Yield	0.00%
50-Day Moving Average	$40.76
Beta	1.31
Avg. Volume	570,811.91
PE Ratio	6.68

52-Week High	$52.24
52-Week Low	$15.50
Market Capitalization	$759.27M
EPS (Annual)	$0.9886
Price to Book	6.35
Revenue Per Employee	$1.09M
Enterprise Value/EBITDA	N/A

RIGL
Rigel Pharmaceuticals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RIGL News

RIGLRigel Pharmaceuticals